SWEDISH ORPHAN/S (SWTUY) Downgraded to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of SWEDISH ORPHAN/S (OTCMKTS:SWTUY) from a hold rating to a sell rating in a research note published on Tuesday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine raised shares of SWEDISH ORPHAN/S from a hold rating to a buy rating in a report on Thursday, July 19th.
SWEDISH ORPHAN/S (OTCMKTS:SWTUY) last announced its earnings results on Wednesday, October 31st. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.02). The company had revenue of $258.63 million for the quarter, compared to the consensus estimate of $261.25 million. SWEDISH ORPHAN/S had a return on equity of 29.63% and a net margin of 25.75%. Research analysts expect that SWEDISH ORPHAN/S will post 0.97 EPS for the current fiscal year.
SWEDISH ORPHAN/S Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Featured Article: What is the Ex-Dividend Date in Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.